secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001193125-25-220721
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics shareholders approve 24.18M share increase and Series B conversion at less than minimum price
--------------------------------------------------------------------------------

- Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.
- Approved issuance of over 19.99% of outstanding common stock upon Series B Preferred conversion at less than Nasdaq minimum price, deemed a potential change of control.
- Proposal 1 (conversion) passed with 5,502,026 votes for, 515,275 against, 35,744 abstentions.
- Proposal 2 (plan amendment) passed with 5,089,862 votes for, 951,598 against, 11,585 abstentions.
- Approximately 54.5% of outstanding shares were present, forming a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312525220721/0001193125-25-220721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312525220721/sabs-20250926.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-220721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer